IMAX Q3 Box Office Blowout Prompts Wedbush Target Hike to $60

What happened

Wedbush raised its IMAX price target to $60 from $54, citing an expected record Q3 global box office of $712 million on IMAX screens, more than double its prior $401 million estimate. This news follows the company's Q2 2026 report that showed revenue of $102.8 million and a backlog decline to 421 systems, which had led to a cautious WAIT rating with an attractive entry at $37. The massive box office beat suggests premium-format demand is stronger than modeled, potentially driving global market share above the 2025 record of 3.8% and validating the bull case. However, the stock is now trading near $43.40, and the new $60 target implies a 38% upside, which may be overly optimistic if the box office strength is concentrated in a few tentpoles and China backlog continues to shrink. Investors should monitor whether the Q3 results, when officially reported, show sustained share gains and backlog stabilization before becoming more constructive.

Implication

The surge in IMAX box office for Q3, if confirmed, would mark a step-change in premium-format adoption and support a higher valuation. However, the master report's bull case value of $51 already assumed global share exceeding 3.9%, and the new $60 target requires continued outperformance across multiple quarters. Key risks remain: backlog contraction, especially from China, and concentration of box office in a few releases, which could lead to mean reversion. The next earnings release will be critical to see if the box office strength translated into higher gross margins and cash flow, and whether backlog stopped shrinking. Until then, the stock appears to be pricing in a perfect outcome, so maintaining a disciplined approach with a buy zone near $37 and trim above $48 seems prudent.

Thesis delta

The thesis has shifted from cautious WAIT to a more neutral-to-bullish stance as the record Q3 box office outperformance directly addresses the concern of insufficient premium share. However, the improvement is concentrated in a single quarter and does not yet resolve the structural issues of declining backlog and China weakness. The bull case probability should be increased modestly, but the base case remains that valuation is full and a pullback would be needed for a comfortable entry.